CYP2B6

Cytochrome P450 2B6 · P20813 · CYP2B6 on Sugi Atlas →

107,679 patent compounds predicted against CYP2B6, 72,173 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL210356	0.74	9/20
SCHEMBL211177	0.57	7/20
SCHEMBL216242	0.56	6/20
SCHEMBL156922	0.51	6/20
SCHEMBL209292	0.51	6/20
Gingerol (SCHEMBL32102)	1.00	4/20
Shogaol (SCHEMBL49054)	1.00	4/20
SCHEMBL158705	1.00	4/20
SCHEMBL32090	0.72	4/20
SCHEMBL120088	0.62	4/20
SCHEMBL152405	0.45	4/20
SCHEMBL38500	0.44	4/20
SCHEMBL185113	0.40	4/20
SCHEMBL29673	1.00	3/20
(+)-Tranylcypromine (SCHEMBL34339)	1.00	3/20
(+)-Tranylcypromine (SCHEMBL40651)	1.00	3/20
(+)-Tranylcypromine (SCHEMBL145650)	1.00	3/20
SCHEMBL149952	1.00	3/20
(+)-Tranylcypromine (SCHEMBL56350)	0.95	3/20
(+)-Tranylcypromine (SCHEMBL56351)	0.95	3/20

Clinical trials — most relevant to CYP2B6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Genetics on Metabolism of Efavirenz	PHASE4	COMPLETED
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Pharmacogenetics of Nicotine Addiction Treatment	PHASE3	COMPLETED
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	PHASE2	WITHDRAWN
Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion	PHASE1/PHASE2	COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)	PHASE1	COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients	PHASE1	COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes	PHASE1	COMPLETED
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone	PHASE1	UNKNOWN
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis	PHASE1	RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B	PHASE1	COMPLETED
A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects	PHASE1	COMPLETED
Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients	PHASE1	UNKNOWN
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	PHASE1	UNKNOWN
Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children	PHASE1	COMPLETED
A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects	PHASE1	COMPLETED
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers	PHASE1	COMPLETED
Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults	EARLY_PHASE1	NOT_YET_RECRUITING
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy	nan	UNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
CYP2B6 Polymorphisms in Methadone Disposition	nan	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients	nan	COMPLETED
Rifampin and Nevirapine Interactions in Young Children	nan	UNKNOWN
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants	nan	COMPLETED
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2B6 binder may also engage these)

Protein	Name	Similarity
P00176	—	1.000	P00176 →
O18809	—	0.999	O18809 →
O55071	—	0.999	O55071 →
P24460	—	0.998	P24460 →
P04167	—	0.997	P04167 →
Q64583	—	0.996	Q64583 →
P12791	—	0.995	P12791 →
P12789	—	0.994	P12789 →
P12790	—	0.992	P12790 →
P00178	—	0.992	P00178 →
P33272	—	0.991	P33272 →
P15123	—	0.991	P15123 →
Q05556	—	0.990	Q05556 →
CYP2A13	Cytochrome P450 2A13	0.990	landscape →
Q05555	—	0.990	Q05555 →
O35293	—	0.990	O35293 →
CYP2A7	Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7)	0.990	landscape →
P10610	—	0.989	P10610 →
P33267	—	0.989	P33267 →
Q8WNE1	—	0.988	Q8WNE1 →
CYP2F1	Cytochrome P450 2F1 (EC 1.14.14.1) (CYPIIF1)	0.988	landscape →
P33264	—	0.987	P33264 →
E9Q5K4	—	0.986	E9Q5K4 →
CYP2C19	Cytochrome P450 2C19	0.986	landscape →
P33263	—	0.986	P33263 →
O93297	—	0.985	O93297 →
P24461	—	0.985	P24461 →
P56656	—	0.984	P56656 →
P00179	—	0.984	P00179 →
P20812	—	0.984	P20812 →